[{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bromfenac","moa":"Cyclooxygenase","graph1":"Neurology","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals for Bromfenac

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          CAMX
                          Not Confirmed
                          CAMX
                          Not Confirmed

                          Details : BromSite-Generic (bromfenac) acts by inhibiting Cox-1 and 2. It is indicated for the treatment of postoperative inflammation and prevention of ocular pain in patients undergoing cataract surgery.

                          Product Name : BromSite-Generic

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          February 14, 2024

                          Lead Product(s) : Bromfenac

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Silverstein Eye Centers

                          Country arrow
                          CAMX
                          Not Confirmed

                          Silverstein Eye Centers

                          Country arrow
                          CAMX
                          Not Confirmed

                          Lead Product(s) : Bromfenac

                          Therapeutic Area : Ophthalmology

                          Study Phase : Phase IV

                          Sponsor : Bausch & Lomb Incorporated | Churchhill Communications | Statistics & Data Corporation

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          March 22, 2019

                          Lead Product(s) : Bromfenac

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase IV

                          Sponsor : Bausch & Lomb Incorporated | Churchhill Communications | Statistics & Data Corporation

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Melissa Toyos

                          Country arrow
                          CAMX
                          Not Confirmed

                          Melissa Toyos

                          Country arrow
                          CAMX
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          May 07, 2013

                          Lead Product(s) : Bromfenac

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Undisclosed

                          Sponsor : Bausch & Lomb Incorporated

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Laboratorios Sophia

                          Country arrow
                          CAMX
                          Not Confirmed

                          Laboratorios Sophia

                          Country arrow
                          CAMX
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          February 17, 2012

                          Lead Product(s) : Bromfenac

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          CAMX
                          Not Confirmed
                          CAMX
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          June 07, 2011

                          Lead Product(s) : Bromfenac

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Toyos Clinic

                          Country arrow
                          CAMX
                          Not Confirmed

                          Toyos Clinic

                          Country arrow
                          CAMX
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          March 08, 2011

                          Lead Product(s) : Bromfenac

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase IV

                          Sponsor : Bausch & Lomb Incorporated

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          CAMX
                          Not Confirmed
                          CAMX
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          September 30, 2010

                          Lead Product(s) : Bromfenac

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank